Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1984 Apr;25(4):433-7.
doi: 10.1128/AAC.25.4.433.

Pharmacokinetics of vancomycin in patients with various degrees of renal function

Pharmacokinetics of vancomycin in patients with various degrees of renal function

G R Matzke et al. Antimicrob Agents Chemother. 1984 Apr.

Abstract

The pharmacokinetics of vancomycin were characterized in 56 patients with different degrees of renal function after an intravenous dose of 18.4 +/- 4.7 mg kg-1 (mean +/- standard deviation). Seven subjects had a creatinine clearance (CLCR) of greater than 60 ml min-1 (group I), 13 had a CLCR of 10 to 60 ml min-1 (group II), and 36 had a CLCR of less than 10 ml min-1 (group III). Serial serum samples (range, 3 to 8) were collected during the 168 h after drug administration. The serum concentration-time profile in all patients demonstrated monoexponential decay. The mean half-lives were 9.1, 32.3, and 146.7 h in groups I, II, and III, respectively. A significant decline in serum clearance (CLS) was also noted (62.7 to 28.3 to 4.87 ml min-1 in groups I, II, and III, respectively). The steady-state volume of distribution varied from 0.72 to 0.90 liter kg-1. There was no significant relationship between the steady-state volume of distribution and CLCR. The observed relationship between CLS and CLCR (CLS = 3.66 + 0.689 CLCR; r = 0.8807) can be utilized to devise dosage schedules for patients with any degree of renal impairment. This relationship was utilized to develop a nomogram for initial and maintenance dosing of vancomycin.

PubMed Disclaimer

References

    1. N Engl J Med. 1966 May 12;274(19):1047-51 - PubMed
    1. Br Med J. 1970 Jul 11;3(5714):80-2 - PubMed
    1. Am J Med Sci. 1971 Aug;262(2):87-92 - PubMed
    1. Acta Med Scand. 1975 Apr;197(4):261-4 - PubMed
    1. Nephron. 1976;16(1):31-41 - PubMed